Kronos Bio Inc
NASDAQ:KRON
Intrinsic Value
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. [ Read More ]
The intrinsic value of one KRON stock under the Base Case scenario is 0.81 USD. Compared to the current market price of 1.03 USD, Kronos Bio Inc is Overvalued by 21%.
Valuation Backtest
Kronos Bio Inc
Run backtest to discover the historical profit from buying and selling KRON stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kronos Bio Inc
Current Assets | 178.8m |
Cash & Short-Term Investments | 173m |
Other Current Assets | 5.8m |
Non-Current Assets | 34.5m |
Long-Term Investments | 2m |
PP&E | 29.9m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 24.7m |
Accounts Payable | 883k |
Accrued Liabilities | 13.8m |
Other Current Liabilities | 10m |
Non-Current Liabilities | 29.5m |
Other Non-Current Liabilities | 29.5m |
Earnings Waterfall
Kronos Bio Inc
Revenue
|
6.3m
USD
|
Operating Expenses
|
-125.2m
USD
|
Operating Income
|
-118.9m
USD
|
Other Expenses
|
6.3m
USD
|
Net Income
|
-112.7m
USD
|
Free Cash Flow Analysis
Kronos Bio Inc
KRON Profitability Score
Profitability Due Diligence
Kronos Bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Kronos Bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
KRON Solvency Score
Solvency Due Diligence
Kronos Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Kronos Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KRON Price Targets Summary
Kronos Bio Inc
According to Wall Street analysts, the average 1-year price target for KRON is 4.34 USD with a low forecast of 2.53 USD and a high forecast of 6.3 USD.
Ownership
KRON Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KRON Price
Kronos Bio Inc
Average Annual Return | -44.31% |
Standard Deviation of Annual Returns | 46.75% |
Max Drawdown | -98% |
Market Capitalization | 60.7m USD |
Shares Outstanding | 60 095 000 |
Percentage of Shares Shorted | 1.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).
Contact
IPO
Employees
Officers
The intrinsic value of one KRON stock under the Base Case scenario is 0.81 USD.
Compared to the current market price of 1.03 USD, Kronos Bio Inc is Overvalued by 21%.